S&P Futures
6,033.75 -4.50 (-0.07%) Dow Futures
44,949.00 -2.00 (-0.00%) Nasdaq Futures
20,956.00 -37.50 (-0.18%) Russell 2000 Futures
2,438.50 +6.10 (+0.25%) Crude Oil
68.97 +0.20 (+0.29%) Gold
2,646.40 +25.10 (+0.96%)
XORTX Therapeutics Inc. (XRTX.V)
| Previous Close | 1.7300 |
| Open | 1.7300 |
| Bid | 1.6500 x N/A |
| Ask | 1.6800 x N/A |
| Day's Range | 1.6100 - 1.7600 |
| 52 Week Range | 1.5400 - 9.3500 |
| Volume | |
| Avg. Volume | 11,617 |
| Market Cap | 5.254M |
| Beta (5Y Monthly) | -0.21 |
| PE Ratio (TTM) | 9.59 |
| EPS (TTM) | 0.1700 |
| Earnings Date | Nov 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireXORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024
● Health consequences of chronically high uric acid and xanthine oxidase in polycystic kidney disease in rats, mice and humans ● CALGARY, Alberta, Oct. 24, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance of an abstract submitted to the American Society of Nephrol
- GlobeNewswire
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
CALGARY, Alberta, Oct. 18, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, today announced that it has closed its registered direct offering and concurrent private placement, announced on October 17, 2024, for the purchase and sale of 810,810 common shares (or pre-funded warrants in lieu thereof) in
